[{"address1": "221 Crescent Street", "address2": "Building 17 Suite 102b", "city": "Waltham", "state": "MA", "zip": "02453", "country": "United States", "phone": "650 394 5230", "website": "https://www.apogeetherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 91, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael Thomas Henderson M.D.", "age": 34, "title": "CEO & Director", "yearBorn": 1990, "fiscalYear": 2023, "totalPay": 1171208, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jane Pritchett V. Henderson", "age": 58, "title": "Chief Financial Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 843643, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Carl Linden Dambkowski M.D.", "age": 39, "title": "Chief Medical Officer", "yearBorn": 1985, "fiscalYear": 2023, "totalPay": 870833, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Noel  Kurdi", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Batters J.D.", "age": 48, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Emily  Cox", "title": "VP & Head of People", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Rebecca  Dabora Ph.D.", "age": 64, "title": "Chief Development Officer", "yearBorn": 1960, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Wendy  Aspden-Curran", "title": "Senior Vice President of Clinical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Drew  Badger Ph.D.", "title": "Senior VP and Head of Regulatory Affairs & Toxicology", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Monica  Forbes", "age": 48, "title": "Senior Vice President of Finance", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 10, "overallRisk": 9, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 49.21, "open": 47.61, "dayLow": 39.07, "dayHigh": 48.34, "regularMarketPreviousClose": 49.21, "regularMarketOpen": 47.61, "regularMarketDayLow": 39.07, "regularMarketDayHigh": 48.34, "forwardPE": -10.100885, "volume": 1366016, "regularMarketVolume": 1366016, "averageVolume": 459416, "averageVolume10days": 434310, "averageDailyVolume10Day": 434310, "bid": 40.96, "ask": 41.15, "bidSize": 100, "askSize": 100, "marketCap": 2335864064, "fiftyTwoWeekLow": 30.84, "fiftyTwoWeekHigh": 72.29, "fiftyDayAverage": 49.0431, "twoHundredDayAverage": 49.358673, "currency": "USD", "enterpriseValue": 1888057728, "floatShares": 29088666, "sharesOutstanding": 43416300, "sharesShort": 7973039, "sharesShortPriorMonth": 6623233, "sharesShortPreviousMonthDate": 1731628800, "dateShortInterest": 1734048000, "sharesPercentSharesOut": 0.1401, "heldPercentInsiders": 0.11694, "heldPercentInstitutions": 1.27286, "shortRatio": 13.25, "shortPercentOfFloat": 0.2062, "impliedSharesOutstanding": 68214200, "bookValue": 12.552, "priceToBook": 3.270395, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -146663008, "trailingEps": -2.43, "forwardEps": -3.8, "52WeekChange": 0.26036227, "SandP52WeekChange": 0.22263205, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "APGE", "underlyingSymbol": "APGE", "shortName": "Apogee Therapeutics, Inc.", "longName": "Apogee Therapeutics, Inc.", "firstTradeDateEpochUtc": 1689341400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "a31551ee-fb27-3439-a3c7-bbfae7df46cb", "messageBoardId": "finmb_1816591253", "gmtOffSetMilliseconds": -18000000, "currentPrice": 41.05, "targetHighPrice": 110.0, "targetLowPrice": 80.0, "targetMeanPrice": 92.28571, "targetMedianPrice": 90.0, "recommendationKey": "none", "numberOfAnalystOpinions": 7, "totalCash": 526048992, "totalCashPerShare": 8.99, "totalDebt": 12140000, "quickRatio": 16.277, "currentRatio": 16.39, "debtToEquity": 1.653, "returnOnAssets": -0.18515, "returnOnEquity": -0.25648, "freeCashflow": -86914000, "operatingCashflow": -133214000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-13"}]